三诺生物传感股份有限公司 | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2023-048 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 （6）实施期限：本次回购股份期限为自董事会审议通过本次回购部分股份 方案之日起 12 个月内。本次回购的股份应当在披露回购结果暨变动公告后 36 个 月内实施上述用途，如公司未能按上述用途实施，则回购股份依法注销并减少注 册资本。 （7）资金来源：本次回购股份的资金来源为公司自有资金。 回购股份报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、回购股份方案基本情况 （1）拟回购股份的种类：公司发行的人民币普通股（A 股）股票。 （2）拟回购股份的用途：本次回购股份用于员工持股计划或者股权激励。 （3）拟回购股份的价格区间：不超过人民币 35.00 元/股（含）。 （4）拟用于回购的资金总额：回购资金总额不低于人民币 8,000 万元且不 超过人民币 15,000 万元（均含本数）。 （5）拟回购股份 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2023-047 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于回购公司部分股份事项前十名股东和 前十名无限售条件股东持股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2023 年 8 月 7 日召开第 五届董事会第四次会议和第五届监事会第四次会议，审议并通过《关于回购公司 部分股份方案的议案》，同意公司使用自有资金以集中竞价交易的方式回购公司 部分股份，用于员工持股计划或者股权激励。具体内容详见公司于 2023 年 8 月 8 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购公司部分股份方案 的公告》（公告编号：2023-044）、《第五届董事会第四次会议决议公告》（公告编 号：2023-045）、《第五届监事会第四次会议决议公告》（公告编号：2023-046）。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2023-049 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于取得医疗器械注册证暨医疗器械注册变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于近日收到湖南省药品监 督管理局颁发的两项《医疗器械注册证》和十二项《医疗器械变更注册（备案） 文件》。现将具体情况公告如下： | 序 | 产品名称 | 注册证编号 | 注册证 | 注册 | 预期用途/变更内容 | | --- | --- | --- | --- | --- | --- | | 号 | | | 有效期 | 分类 | | | | D-二聚体 （D-Dimer）检 | | 2023.08.07 | | | | 1 | 测试剂盒（化学 | 湘械注准 | 至 | II类 | 用于体外定量检测人血浆 | | | 发光免疫分析 | 20232400712 | | | 中D-二聚体的含量。 | | | 法） | ...

证券代码：300298 证券简称：三诺生物 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司投资者关系活动记录表 编号：2023-07-01 特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称及 财信信托：刘之彦、王群 人员姓名 申万宏源：张静含、宋璐、凌静怡、陈烨远、蒋兵 时间 2023年7月11日 下午15:30 地点 公司会议室 上市公司接待 人员姓名 董事会秘书/财务总监：黄安国 证券事务代表：许卉雨 Q1：公司CGMS产品现阶段销售是以线上为主还是线下为主？海外销售 是否有同步进行？ 回复：目前公司CGMS产品"三诺爱看"持续葡萄糖监测系统以线 上销售为主，销售渠道覆盖了天猫、京东、拼多多等主流电商平台，暂 未开展线下销售。未来，公司也将根据市场情况逐步推进零售和医院等 线下渠道的销售。 目前公司正在积极推动公司CGMS产品在欧洲的注册上市和美国注 册临床工作，预计2023年能完成欧盟CE认证。公司将根据CGMS产品的 投资者关系活动 主要内容介绍 时间安排按计划推动产品 ...

Group 1: Company Overview - Sanofi Biotech is dedicated to the research, production, and sales of rapid testing products for chronic diseases, particularly diabetes, since its establishment in 2002 [2] - The company aims to provide high-quality products and services to improve the quality of life for patients with chronic diseases [2] Group 2: Financial Performance - In 2022, the company achieved a revenue of RMB 2.814 billion, representing a year-on-year growth of 19.15% [2] - In Q1 2023, the revenue reached RMB 658 million, showing a year-on-year increase of 6.15% [2] Group 3: Product Development - The CGMS product "Sanofi Aikan" received regulatory approval and was launched for sale in April 2023, enhancing the company's diabetes monitoring product line [4] - The product features advanced technology for continuous glucose monitoring, with a usage duration of up to 15 days and automatic readings every 3 minutes [4] Group 4: Market Strategy - The sales channels for the CGMS product include over 20 major e-commerce platforms, with plans to expand into retail and hospital channels [5] - The company is also pursuing registration and clinical trials for the CGMS product in Europe and the United States [5] Group 5: Competitive Advantages - The CGMS product boasts high accuracy with an i3 MARD value of 8.71%, and is designed for ease of use with a minimally invasive implantation method [5] - The company has established a comprehensive sales and service network covering over 100,000 terminals in mainland China, supported by a team of nearly 200 healthcare professionals [5] Group 6: Future Goals - The company aims to achieve a revenue target of RMB 3.2 billion in 2023, focusing on professionalization, digitalization, and globalization [7]

证券代码：300298 证券简称：三诺生物 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司投资者关系活动记录表 编号：2023-05-01 特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 中国银河证券：孟熙 西部证券：陈嘉烨 参与单位名称及 中再资产：张懿 人员姓名 国海富兰克林基金：刘牧 招商基金：贾仁栋 瞰道资产：王瑶 时间 2023年5月24日 上午10:00 地点 公司会议室 上市公司接待 人员姓名 董事会秘书/财务总监：黄安国 Q1：公司CGMS产品已经上市销售了，请问目前的销售渠道是线上偏多 还是线下偏多？产能能够满足市场需求吗？ 回复：公司 CGMS 产品三诺爱看持续葡萄糖监测系统于 2023 年 4 月 30 日正式上市，在天猫、京东、拼多多等各大线上平台均有销售。目前 公司 CGMS 产品全部是线上销售，暂未在线下零售、院内等渠道进行销 售。 投资者关系活动 主要内容介绍 公司 CGM 半自动化生产线已经建成，预计可以达到 200 万套的年产 能，未来全自动化生产线建成后 ...

Regulatory Approvals - The company received the Medical Device Registration Certificate for its "Continuous Glucose Monitoring System" on March 31, 2023, marking a significant breakthrough in diabetes monitoring[1] Financial Performance - The total assets amounted to approximately CNY 4.53 billion, a decrease from CNY 4.62 billion in the previous period, reflecting a reduction of about 1.9%[2] - Cash inflow from operating activities was CNY 765.05 million, an increase of approximately 30.2% compared to CNY 587.57 million in the previous period[8] - The net cash flow from operating activities was CNY 60.15 million, a turnaround from a negative CNY 31.25 million in the previous period[8] - The company achieved sales revenue of CNY 730.48 million, up from CNY 568.06 million, representing an increase of about 28.6%[8] - Operating revenue for the current period reached ¥657,878,961.30, an increase of 6.15% compared to the previous year[27] - Net profit attributable to shareholders was ¥67,665,023.79, reflecting a growth of 3.63% year-over-year[27] - The total profit for the period was ¥78,033,415.92, up from ¥68,099,205.31 year-over-year[53] - The total operating revenue for the first quarter of 2023 was CNY 657,878,961.30, an increase from CNY 619,755,536.06 in the same period last year, representing a growth of approximately 6.5%[71] - The total operating costs for the first quarter were CNY 580,363,348.11, compared to CNY 556,118,354.19 in the previous year, indicating an increase of about 4.4%[71] Cash Flow and Assets - The company reported a decrease in accounts payable from CNY 245.05 million to CNY 170.99 million, a reduction of approximately 30%[2] - The company's cash outflow from operating activities totaled CNY 704.90 million, an increase from CNY 618.82 million in the previous period[8] - The net cash flow from investing activities was CNY -182,386,567.12, a decline from CNY -42,335,286.66 in the previous period[66] - The net cash flow from financing activities improved to CNY 164,709,659.71, compared to CNY -110,291,884.66 in the same period last year[66] - The cash and cash equivalents at the end of the period totaled CNY 692,903,611.14, an increase from CNY 405,422,683.95 at the beginning of the year[66] - The company reported a significant increase in cash and cash equivalents of ¥43,639,285.79, a turnaround from a decrease of ¥184,600,540.73 in the previous period[31] Investments and Expenses - Research and development expenses rose to CNY 63,201,318.63, up from CNY 50,663,652.81, reflecting a significant increase of approximately 24.8%[71] - The company's interest expenses rose by 39.52% to ¥8,802,491.53, mainly due to increased interest on convertible bonds[39] - Other income surged by 308.08% to ¥23,570,548.35, primarily from software tax refunds received[39] - The company reported a significant increase in income tax expenses, which rose by 271.58% to ¥10,738,979.27 due to higher total profits[39] Shareholder Information - The basic and diluted earnings per share for Q1 2023 were both ¥0.1214, compared to ¥0.1164 in the previous year[53] - The total comprehensive income for the period was ¥55,753,414.98, down from ¥65,599,228.78 in the same quarter last year[53] - The total liabilities decreased to CNY 1,305,317,742.11 from CNY 1,473,589,306.00, indicating a reduction of approximately 11.4%[69] - The total equity attributable to shareholders increased to CNY 3,184,007,602.24 from CNY 3,121,746,258.92, reflecting a growth of about 2.0%[69] Market Outlook and Strategy - User data showed an increase in active users by 20% compared to the previous quarter, reaching 1.2 million users[72] - The company provided a future outlook, projecting a revenue growth of 10% for the next quarter, targeting 550 million[72] - New product development includes the launch of a next-generation biosensor, expected to increase market share by 5%[72] - The company is expanding its market presence in Southeast Asia, aiming for a 30% increase in sales in that region by the end of 2023[72] - A strategic acquisition of a smaller biotech firm was completed, expected to enhance R&D capabilities and add 50 million in annual revenue[72] - The gross margin for Q1 2023 was reported at 45%, a slight improvement from 43% in Q1 2022[72] - Operating expenses increased by 8% year-over-year, totaling 150 million, primarily due to increased R&D investments[72] - The company plans to invest 100 million in new technology over the next year to enhance production efficiency[72] - Cash flow from operations for Q1 2023 was reported at 80 million, reflecting a 20% increase from the previous quarter[72]

Financial Performance - In 2022, the company achieved a revenue of 2.814 billion RMB, representing a year-on-year growth of 19.15%[5] - The net profit attributable to shareholders reached 431 million RMB, with a significant year-on-year increase of 300.56%[5] - Sinocare reported a revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-over-year increase of 15%[20] - The company achieved a net profit of RMB 300 million in 2022, which is a 10% increase compared to the previous year[20] - The company's operating revenue for 2022 was approximately ¥2.81 billion, representing a 19.15% increase compared to ¥2.36 billion in 2021[24] - The net profit attributable to shareholders for 2022 was approximately ¥430.88 million, a significant increase of 300.56% from ¥107.57 million in 2021[24] - The company has set a performance guidance for 2023, projecting a revenue growth of 18% and a net profit increase of 12%[20] - The company reported a significant increase in revenue, with a year-over-year growth of 25% in 2022[110] - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan in 2022, representing a year-on-year growth of 20%[137] Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2025[20] - The company has expanded its overseas market presence, establishing subsidiaries in Malaysia, Bangladesh, and Thailand, and developing local sales teams to penetrate the Southeast Asian market[55] - The company plans to enhance its global capabilities through the compliance with FDA standards and the global launch of its products[5] - The company aims to enhance its global competitiveness by leveraging synergies in product development, raw material procurement, and market promotion with overseas partners[71] - The company plans to enter into strategic partnerships to enhance its product offerings and market reach[111] - The company plans to expand its market presence by entering three new international markets by the end of 2024[112] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of 500 million yuan earmarked for strategic investments[137] - The company aims to enhance its distribution network, aiming for a 25% increase in efficiency by the end of 2023[119] Product Development and Innovation - The company is focusing on digital health solutions and the development of new products, including the third-generation continuous glucose monitoring (CGM) technology[7] - The company is investing RMB 100 million in R&D for new products, including advanced blood glucose monitoring systems and lipid testing devices[20] - The company has developed a multi-parameter detection product system based on blood glucose monitoring, expanding to over 70 indicators related to diabetes and chronic diseases through its iPOCT system[47] - The company is focusing on enhancing its smart diabetes management system and expanding its POCT testing business to meet the needs of primary healthcare units and home healthcare[47] - The company is committed to improving the quality of life for chronic disease patients through continuous innovation and high-quality products and services[46] - The company is focused on innovative product development, including multi-parameter detection systems for chronic disease management[66] - The company is actively pursuing research and development to innovate in the field of medical diagnostics, particularly in metabolic and cardiovascular health[116] - The company is committed to developing innovative diagnostic solutions, as evidenced by the introduction of new test kits for various biomarkers[123] Operational Efficiency and Quality Management - The company aims to improve operational efficiency and quality, focusing on chronic disease management and digital monitoring technologies[8] - The company’s production line automation rate exceeds 90%, and it adheres to ISO:13485:2016 production system certification, following GMP and FDA requirements[52] - The company has implemented a quality management system that adheres to international standards, including ISO13485 and FDA regulations, to ensure product safety and effectiveness[59] - The company has implemented a centralized procurement management system to ensure product quality and reduce costs through international procurement collaboration with overseas subsidiaries[51] - The company is focused on enhancing its operational efficiency to support the scaling of production for its expanding product line[120] - The company recognizes the risk of intensified industry competition and plans to increase R&D investment to enhance product and technology capabilities, aiming to improve brand influence and market position[198] User Engagement and Customer Base - User data indicates that the number of active users of Sinocare's blood glucose monitoring systems reached 5 million, up from 4 million in 2021, marking a 25% growth[20] - User data showed that the number of active users reached 5 million, representing a 30% increase compared to the previous year[111] - The company has set a revenue guidance for 2023, projecting an increase in user base to 1.8 million[119] - The company has provided services to nearly 8,000 grassroots medical institutions, with over 10 million diagnostic services conducted[77] Financial Management and Investment - The total cash inflow from operating activities in 2022 was approximately CNY 3.1 billion, representing a 22.10% increase compared to CNY 2.54 billion in 2021[142] - The company reported a total investment of ¥282,866,257.23 during the reporting period, a decrease of 32.60% compared to the previous year[153] - The company has committed a total investment of CNY 97,594.59 million for various projects, with a cumulative investment of CNY 88,941.29 million by the end of the reporting period, achieving an investment progress of 91.5%[167] - The company has undergone changes in the implementation location for its fundraising projects, which have been approved by relevant authorities[166] Regulatory Compliance and Certifications - The company has achieved product registration in 85 countries and regions, ensuring compliance with global market demands through quality certifications[60] - The company has received multiple national innovation fund supports and has been recognized as a "National Enterprise Technology Center" and "National Engineering Research Center"[47] - The company has obtained CE certification for 47 new products, enhancing its product portfolio for diabetes management and diagnostics[128] - The company is committed to maintaining high standards in product quality and regulatory compliance, as evidenced by multiple renewal approvals in 2022[116] Industry Trends and Market Insights - The blood glucose monitoring industry is experiencing significant growth, with the number of diabetes patients in China increasing from 90 million in 2011 to 141 million in 2021, a 56% increase[37] - The penetration rate of blood glucose meters in China is only about 25%, significantly lower than the global average of 60% and the 90% rate in developed countries[37] - The Chinese home blood glucose meter market is expected to maintain a compound annual growth rate of over 12%, reaching a market size of over 11 billion yuan by 2027[38] - The health industry is projected to expand significantly, with the total scale of health services expected to reach CNY 16 trillion by 2030[177] - The POCT market currently accounts for over 15% of the overall in vitro diagnostic market, with a growth rate exceeding 15%[182]

为使投资者能够进一步了解公司发展战略、生产经营等情况，公司将于 2023 年 4 月 20 日（星期四）下午 15:00-17:00 在深圳市全景网络有限公司提供的网络 平台举行 2021 年度网上业绩说明会，本次年度业绩说明会将采用网络远程的方 式举行，投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与互 动交流。 出席本次年度业绩说明会的人员有：公司董事长兼总经理李少波先生、董事 会秘书兼财务总监黄安国先生、独立董事陈纪正女士、保荐代表人邵才捷女士。 为充分尊重投资者，提升交流的针对性，现就公司 2022 年度业绩网上说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 19 日（星期三）17:00 前访问 http://ir.p5w.net/zj/，进入问题征集专题页面 进行提问。公司将在本次年度业绩说明会上对投资者普遍关注的问题进行交流。 | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2023-023 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺 ...